Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah A. Meadows, Sarah E. M. Herman, Adam Kashishian, Bart Steiner, Amy J. Johnson, John C. Byrd, Jeffrey W. Tyner, Marc M. Loriaux, Mike Deininger, Brian J. Druker, Kamal D. Puri, Roger G. Ulrich, Neill A. Giese

Blood (2011) 117 (2): 591–594.

https://doi.org/10.1182/blood-2010-03-275305

Published: 2011

Includes: Supplemental data

Journal Articles

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber L. Gordon, Amy J. Wagner, Nyla A. Heerema, Weiqiang Zhao, Joseph M. Flynn, Jeffrey Jones, Leslie Andritsos, Kamal D. Puri, Brian J. Lannutti, Neill A. Giese, Xiaoli Zhang, Lai Wei, John C. Byrd, Amy J. Johnson

Blood (2010) 116 (12): 2078–2088.

https://doi.org/10.1182/blood-2010-02-271171

Published: 2010

Journal Articles

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Blood (2010) 116 (9): 1460–1468.

https://doi.org/10.1182/blood-2009-06-222943

Published: 2010

Includes: Supplemental data

Journal Articles

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

Ian W Flinn, M.D., Ph.D., John C. Byrd, M.D., Richard R Furman, MD, Jennifer R Brown, MD, PhD, Don M Benson, MD, PhD, Steven E Coutre, MD, Brad S Kahl, M.D., B. Douglas Smith, M.D., Nina D. Wagner-Johnston, MD, Stephen E Spurgeon, MD, Neill A. Giese, Ph.D., Albert S Yu, MD

Blood (2009) 114 (22): 922.

https://doi.org/10.1182/blood.V114.22.922.922

Published: 2009

Journal Articles

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.

Brian J Lannutti, Sarah A Meadows, Adam Kashishian, Bart Steiner, Galina Pogosov, Olga Sala-Torra, Amy J Johnson, John C. Byrd, Jerald Radich, Neill A. Giese

Blood (2009) 114 (22): 286.

https://doi.org/10.1182/blood.V114.22.286.286

Published: 2009

Journal Articles

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

Sarah E. May, Adam Kashishian, Thomas S. Lin, MD, PhD, Jeffrey A. Jones, MD, Joseph M. Flynn, DO, MPH, Roger G. Ulrich, PhD, Hao Chen, PhD, Albert S. Yu, MD, PhD, Kamal D. Puri, PhD, BSc, MSc, Brian J. Lannutti, PhD, Neill A. Giese, PhD, John C. Byrd, MD, Amy J. Johnson, PhD

Blood (2008) 112 (11): 3165.

https://doi.org/10.1182/blood.V112.11.3165.3165

Published: 2008

Journal Articles

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

Brian J Lannutti, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Sarah May, Amy J. Johnson, Roger G. Ulrich, Albert Yu, Michael W. Gallatin, John C. Byrd, MD, Kamal D. Puri, Neill A. Giese

Blood (2008) 112 (11): 16.

https://doi.org/10.1182/blood.V112.11.16.16

Published: 2008

Journal Articles

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

Hiroshi Ikeda, MD, PhD, Teru Hideshima, MD, PhD, Yutaka Okawa, MD, PhD, Sonia Vallet, MD, Samantha Pozzi, Loredana Santo, MD, Gullu Gorgun, Mariateresa Fulciniti, Noopur S. Raje, MD, Giulia Perrone, Nikhil Munshi, MD, Paul Richardson, MD, Brian J Lannutti, Kamal D. Puri, Neill A. Giese, Kenneth C. Anderson, MD

Blood (2008) 112 (11): 2753.

https://doi.org/10.1182/blood.V112.11.2753.2753

Published: 2008

Journal Articles

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

Jennifer J. Clark, Jan Cools, David P. Curley, Jin-Chen Yu, Nathalie A. Lokker, Neill A. Giese, D. Gary Gilliland

Blood (2004) 104 (9): 2867–2872.

https://doi.org/10.1182/blood-2003-12-4446

Published: 2004

NARROW

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

PI3K/p110δ is a novel therapeutic target in multiple myeloma

Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies.

CAL-101, An Oral p110δ Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment.

CAL-101, a Selective Inhibitor of the p110δ Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease

CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies

CAL-101, a Specific Inhibitor of the p110δ Isoform of Phosphatidylinositide 3-Kinase Induces Cytotoxicity in Multiple Myeloma (MM)

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only